Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What Makes a Great Manuscript?

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Transcatheter or Surgical Aortic-Valve Replacement at 7 Years.

The New England journal of medicine·2026
Same author

Integrative Clinical-Molecular Modeling Identifies <i>LRRN4CL</i> as a Determinant of Structural and Functional Myocardial Improvement.

bioRxiv : the preprint server for biology·2026
Same author

Retrograde perfusion of the dorsalis pedis artery versus traditional distal perfusion catheter use in venoarterial extracorporeal membrane oxygenation.

JTCVS open·2026
Same author

Modifying a traditional femoral venoarterial extracorporeal membrane oxygenation cannulation strategy and circuit to improve distal limb hemodynamics.

JTCVS open·2026
Same author

Local amiodarone delivery via an extracellular collagen matrix patch to reduce new-onset postoperative atrial fibrillation.

JTCVS open·2026

Related Experiment Video

Updated: Jun 8, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Hematologic effects of continuous flow left ventricular assist devices.

Mark S Slaughter1

  • 1Division of Thoracic and Cardiovascular Surgery, University of Louisville, 201 Abraham Flexner Way, Louisville, KY 40202, USA. mark.slaughter@louisville.edu

Journal of Cardiovascular Translational Research
|September 14, 2010
PubMed
Summary

Continuous flow left ventricular assist devices (CF-LVAD) can cause bleeding, particularly gastrointestinal bleeding, due to acquired von Willebrand

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Experiment Videos

Last Updated: Jun 8, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Biomedical Engineering

Background:

  • Continuous flow left ventricular assist devices (CF-LVADs) are increasingly used for heart failure treatment.
  • While CF-LVADs show low rates of hemolysis and thrombosis, bleeding complications remain a significant concern.
  • Understanding the hematologic effects of CF-LVADs is crucial for patient management.

Purpose of the Study:

  • To investigate the hematologic effects associated with continuous flow left ventricular assist device (CF-LVAD) support.
  • To identify the mechanisms contributing to bleeding complications in CF-LVAD patients.
  • To explore potential strategies for preemptive treatment and improved management of bleeding events.

Main Methods:

  • Review of recent clinical studies and evidence regarding CF-LVAD support.
  • Analysis of hematologic parameters including hemolysis, thrombosis, and bleeding incidence.
  • Investigation into the role of blood flow rheology, acquired von Willebrand's disease, and fibrinolytic system activation.

Main Results:

  • Gastrointestinal bleeding, linked to angiodysplasia and arteriovenous malformations, is more common with CF-LVADs.
  • Acquired von Willebrand's disease, resulting from reduced high molecular weight von Willebrand's factor multimers, is observed.
  • Activation of the fibrinolytic system and decreased platelet number/function are noted during CF-LVAD support.

Conclusions:

  • CF-LVAD support induces complex and dynamic hematologic changes, necessitating adjustments in antiplatelet therapy.
  • Pre-implant screening for angiodysplasia and von Willebrand's disease may enable effective preemptive treatment.
  • Further research is required to fully define these hematologic effects and develop better bleeding management strategies.